RIPK3 and neoplasm: RIPK3 has been found to be epigenetically silenced in breast and pancreatic cancer tissue14, 15 and in melanoma cell line.16 In tumor models, loss of RIPK3 aided a TAK1-induced inflammation model of hepatocarcinogenesis,17 whereas loss of RIPK3 in combination with internal tandem duplication mutations of FMS-like tyrosine kinase-3 led to an increase in leukemia in vivo, which was because of the absence of inflammasome activation.18 Expression of RIPK3 in patient samples also has been associated with disease outcome.